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Background: Several surveys in the last 50 years have repeatedly indicated that Belgium is affected by mild
iodine deficiency. Within the framework of the national food and health plan in Belgium, a selective, progres-
sive, and monitored strategy was proposed in 2009 to optimize iodine intake. The objective of the present study
was to perform a health economic evaluation of the consequences of inadequate iodine intake in Belgium,
focusing on undisputed and measurable health outcomes such as thyroid nodular disease and its associated
morbidity (hyperthyroidism).
Methods: For the estimation of direct, indirect, medical, and nonmedical costs related to thyroid nodular diseases
in Belgium, data from the Federal Public Service of Public Health, Food Chain Safety and Environment, the
National Institute for Disease and Disability Insurance (RIZIV/INAMI), the Information Network about the
prescription of reimbursable medicines (FARMANET), Intercontinental Marketing Services, and expert opinions
were used. These costs translate into savings after implementation of the iodization program and are defined as
costs due to thyroid nodular disease throughout the article. Costs related to the iodization program are referred
to as program costs. Only figures dating from before the start of the intervention were exploited. Only adult and
elderly people (18 years) were taken into account in this study because thyroid nodular diseases predomi-
nantly affect this age group.
Results: The yearly costs due to thyroid nodular diseases caused by mild iodine deficiency in the Belgian adult
population are *e38 million. It is expected that the iodization program will result in additional costs of
*e54,000 per year and decrease the prevalence of thyroid nodular diseases by 38% after a 4–5-year period. The
net savings after establishment of the program are therefore estimated to be at least e14 million a year.
Conclusions: Optimization of iodine intake in Belgium should be quite cost effective, if only considering its
impact on nodular thyroid disease. There are likely added benefits relating to more optimal thyroid hormone
influenced brain development that are more difficult to estimate but may be even more important.
Introduction
Despite a worldwide successful implementation of io-dine fortification and supplementation programs over
the last 4 decades, iodine deficiency remains a public heath
problem in Europe. In 2004, it was estimated that of the 2
billion people around the world at risk of iodine deficiency,
20% live in Europe (1). Over the last 2 decades, extraordinary
progress has been achieved in decreasing the prevalence of
iodine deficiency disorders by increasing the number of
people with access to iodized salt (2). However, this has not
been the case in Europe, where, compared to other regions in
the world, iodized salt coverage is low, reaching only 27% of
households (3).
Several surveys in the last 50 years have repeatedly indi-
cated that Belgium is affected bymild iodine deficiency (MID)
(4–6). In 1998, a representative survey in Belgian school
children showed a median urinary iodine concentration of
80mg/L (4), lower than the optimal urinary median values of
100–199 mg/L in the population (7). Consequently, optimizing
iodine intake was chosen among several other nutritional
issues as a priority by the Ministry of Health in its ‘‘National
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Nutrition and Health Plan for Belgium’’ for the period 2005–
2010. Within the framework of this plan, a selective, pro-
gressive, and monitored strategy was proposed to optimize
iodine intake in Belgium.
In an agreement between the bread sector and the Ministry
of Health, FoodChain Safety and Environment, signed inApril
2009, it was established that from then onward, all breads
produced would be fortified with iodized salt (10–15ppm).
This choice stems from the fact that it is easier to control and
regulate the iodine content in one food item rather than in
several items. Also the implementation is easier as bread is
mainly made for local consumption. A selective approach is
particularly relevant in countries affected byMID like Belgium
to avoid an increase of iodine beyond the optimal intake.
The fortification of bread with iodine has already been
implemented with success in other countries like The Neth-
erlands (8) and Denmark (9,10). To be truly selective this
strategy implies that other potential sources of iodine should
be avoided or at least maintained constant to avoid uncon-
trolled variation of iodine intake in the population.
Because a transitory increase of hyperthyroidism may oc-
cur in case of rapid increase of iodine intake, in particular in
the elderly population with multinodular goiter, a progres-
sive, step-by-step increase of iodine intake is preferred (11).
This notion is particularly important because small variations
in daily iodine intake are sufficient to affect thyroid function
(12–14).
The results of the national food consumption survey in
adults (2004) showed that the bread consumption amounts to
120 g/day (P25: 82 g/day; P75: 150 g/day) and is the most
important source of salt intake in Belgium (15).
Considering an estimated daily iodine intake of 80 mg of
iodine in Belgium (4), the strategy is aiming at an initial in-
crease in daily iodine intake of 30 mg during the first 5 years. In
a second phase, taking into account the results of the moni-
toring program, a further increase of 40mg of daily iodine
intake is aimed at to attain an average intake of 150mg of
iodine over a period of 10 years (16).
The drawback of a selective and progressive strategy is that
some people, who only eat very little bread, don’t benefit from
the intervention such as weaning infants, ethnic groups,
people on a weight-loss or low-carbohydrate diet, and per-
sons with celiac disease.
Monitoring will be based on the determination of urinary
iodine concentrations in a representative sample of school-
aged children and pregnant women every 4–5 years, as well
as on the evaluation of thyroid function in pregnant women
and thyroid-stimulating hormone (TSH) concentrations in
newborns. Data on neonatal TSHwill be collected from the six
reference centers performing the screening of congenital hy-
pothyroidism in Belgium.
Further, the possible increase of any adverse effects (iodine-
induced hyperthyroidism), due to the implementation of the
program, will be monitored via follow-up of the use of anti-
thyroid drugs and radio-iodine (I-131) therapy in Belgium.
Previous studies have shown that iodine fortification is
both cost effective and has a high benefit/cost ratio, particu-
larly if iodine deficiency is severe or moderate (17).
It is believed that a program for the control of MID in
Belgium is worthwhile only, in health economic terms, if the
societal costs of the program are lower than the saved costs
that result from the correction of the deficiency.
The health economic advantages of avoiding endemic
goiter and mental retardation in case of severe iodine defi-
ciency are quite obvious. On the contrary, the benefit of cor-
rectingMID is less obvious. Themain consequences ofMID in
the adult population are a high prevalence of multinodular
goiter and thyroid nodules, which may be responsible of
hyperthyroidism (18–23). In addition, it has been suggested
that iodine supplementation improves cognition in mildly
iodine-deficient children (24).
The objective of the present study was to perform, from the
perspective of the healthcare sector (combining patient and
insurer cost), a health economic evaluation of the conse-
quences of inadequate iodine intake in Belgium, focusing on
undisputed and measurable health outcomes such as nodular
disease and its associated morbidity (hyperthyroidism) in the
adult population. Such a health economic estimation is useful
for policy makers to appraise whether the allocated resources
for optimizing iodine intake in Belgium are well spent.
Material and Methods
Costs due to the iodization program
Total iodization program costs (PC) include costs of social
marketing to attain public acceptance of (or preference for)
the fortified food, costs of quality control and quality assur-
ance of salt iodization in bread by producers and of gov-
ernmental monitoring and evaluation activities, costs of any
campaign or publication stimulating iodine supplementation,
and costs of the monitoring program for a period of 4–5
years. Monitoring of TSH in newborns is free as the data are
available already. The implementation of the program does
not include costs of supplying iodized salt as this is already
on the market, technology cost, and costs for equipment,
land, labor, maintenance, and electricity. The small difference
of price between iodized salt and noniodized will not affect
the cost of bread production and will not increase the price of
the product.
In Belgium the salt content of bread is regulated by law and
monitored on regularly by the Federal Agency for Safety of
the Food Chain (FASFC). From April 2009 onward, FASFC
simultaneously verifies the concentration of iodine in salt
used by the bakers for the manufacture of bread, by checking
the label and/or product information of the iodized salt used.
These concentrations as such are not analyzed.
Therefore these costs are negligible.
Costs related to thyroid nodular disease in Belgium
Costs related to thyroid nodular disease translate into
savings after implementation of the iodization program and
are defined as costs due to thyroid nodular disease (TC)
throughout the article.
Only adult and elderly people (18 years) were taken into
account in this study because thyroid nodular disease pre-
dominantly affects this age group. Further, only prevention of
nodular disease (multinodular goiter and thyroid nodules)
and its associated morbidity (hyperthyroidism) was included
in this study. Some other saved costs (due to better cognition,
higher productivity, etc.) (24–28) are important too but very
difficult to assess and therefore excluded, which makes the
results more conservative. Hypothyroidism is excluded in this
study because this pathology is mainly due to autoimmune
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diseases, which are not related to iodine deficiency. Epide-
miological studies have shown that hypothyroidism is more
prevalent in populations with a high iodine intake (20,29–32)
or in severe iodine deficiency (2). Mild-to-moderate iodine
deficiency is not associated with hypothyroidism (20), al-
though the exact association between the level of iodine intake
in a population and the occurrence of hypothyroidism is not
clear. Finally, costs related to work disability, including days
of absence from employment, were not included in this study.
No data are available in Belgium about the true prevalence
of thyroid nodular diseases (including multinodular goiter
and thyroid nodules) in the adult population, as no studies
were performed in the past.
Therefore, prevalence data from a country with as much as
possible the same demographic characteristics, the same salt
iodization history, same intervention program, and same io-
dine status, food consumption pattern, and hospitalization
rate for iodine deficiency disorders were used.
In Denmark, iodization of salt was prohibited from 1982
until 1998, when an optional iodization of salt was initialized.
This led to only a limited use of iodized salt, so from the year
2000 iodization of all household salt and salt used in the bread
industry was made mandatory to a level of 13 ppm iodine
(33). Denmark prospectively evaluated the effect of 4 years of
mandatory iodization of salt (13 ppm iodine) on thyroid vol-
ume in two regional areas with, respectively, mild (the
northern part of Copenhagen, eastern Denmark; median uri-
nary iodine concentration of 61mg/L before mandatory for-
tification) and moderate (Aalborg, western Denmark; median
urinary iodine concentration of 45 mg/L before mandatory
fortification) iodine deficiency.
Two separate cross-sectional studies were performed be-
fore (n¼ 4649) and after (n¼ 3570) the iodization. Women
aged 18–22, 25–30, 40–45, and 60–65 years and men aged 60–
65 years were examined. Before the iodization, 17.6% of the
participants had thyroid enlargement, whereas, after the io-
dization, this percentage decreased to 10.9% (33). This is a
relative decrease of 38%.
Denmark seems to be the country where salt iodization
history is best comparable with the situation in Belgium. A
comparison of demographic information, hospitalization rate
for thyroid disorders, and food consumption of some key
products between Belgium and Denmark can be found in
Table 1.
As a starting point for this study the prevalence of thyroid
enlargement in Denmark in the adult population (17.6%) be-
fore mandatory iodization was used to estimate the preva-
lence of thyroid disorders (multinodular goiter and thyroid
nodules) in the Belgian population. Thyroid enlargement in
the Danish studies was defined as a thyroid volume greater
than 18mL for women and 25mL for men. These values
correspond to the mean þ 3 standard deviation values in
iodine-sufficient populations (33).
It could be derived that before the introduction of the salt
iodization intervention in 2009, about 1,490,892 adult persons
were suffering from multinodular goiter and thyroid nodules
Table 1. Demographic Data, Hospitalization Rate for Thyroid Disorders, and Food Consumption
of Some Key Products in Denmark and Belgium
Demographic indicators Belgium Denmark
Total population
Males 5,224,309 2,712,666
Females 5,442,557 2,763,125
Total adult population
Males 4,102,708 2,089,836
Females 4,368,270 2,170,471
Women per 100 men 104.2 101.9
Life expectancy at birth
Males 77.46 76.26
Females 83.51 80.70
Proportion of the population
Aged 20–39 years 26.0 25.2
Aged 40–59 years 28.4 27.9
Aged 60–79 years 17.9 18.3
Aged 80 years and more 4.7 4.1
Crude rate of net migration 4.86 5.32
Crude birth rate 11.67 11.84
Crude death rate 9.49 9.94
Food consumption
Consumption of fish and seafood 24 25 g/day 18 19 g/day
Consumption of dairy (products) 203 188 g/day 386 283 g/day
Used dietary assessment method 224-hour recall 7-day record
Hospitalization rate
Number of hospitalizations per 100,000
(whole population 2006)
17,770 21,666
Number of hospitalizations for thyroid
disorders per 100,000 (adult population 2006)
70.5 58.7
Sources: EUROSTAT 2008, Federal Public Service of Health in Belgium, Stat Bank in Denmark, and EFSA Concise Database, 2008.
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in Belgium. After a 4–5-year period of the intervention being
in place, it is assumed that this number will decrease by about
38% to 924,353 adult persons with multinodular goiter and
thyroid nodules, as was the case in Denmark.
For the estimation of direct, indirect, medical, and non-
medical TC in the adult population in Belgium, data from
the Federal Public Service of Public Health, Food Chain
Safety and Environment, the National Institute for Disease
and Disability Insurance (RIZIV/INAMI), the Information
Network about the prescription of reimbursable medi-
cines (FARMANET), Intercontinental Marketing Services
(IMS), and expert opinions were used. Only figures dating
from before the start of the intervention (before 2009) were
exploited.
To determine the percentage of persons undergoing sur-
gery for multinodular goiter and thyroid nodules, data from
the Federal Public Service of Health, Food Chain Safety and
Environment were used. These include data from all seven
insurance companies in Belgium and the public center for
social welfare (OCMW). To calculate the costs of surgery and
related costs (hospital stays), these data were linked with the
data from RIZIV/INAMI, which include only data from all
seven insurance companies in Belgium (excluding OCMW
and insurance for invalid persons).
The number of adult persons (18 years) undergoing sur-
gery for multinodular goiter or thyroid nodules in Belgium
was 4856 in 2003, 4925 in 2004, 4794 in 2005, 4814 in 2006, and
4973 in 2007, which resulted in a mean of 4873 per year or
more or less 0.33% of the Belgian adult population suffering
from thyroid nodular diseases. Only hospitalizations includ-
ing thyroid nodular diseases as principal diagnosis were ta-
ken into account. Costs for surgery per year, over the years
2005–2007, including hospital stays, blood tests, metabolic
therapy, pharmaceuticals, diagnosis, and clinical biology can
be found in Table 2. The total average cost per year related to
surgery for thyroid nodular diseases was estimated to be
e13,128,807.
To assess the percentage of people with multinodular goi-
ter or thyroid nodules going to the general practitioner or the
specialist in the hospital, data about the number of adult
persons (18 years) using antithyroid medications (both re-
imbursed [FARMANET] and not reimbursed [IMS data]
medication) and data about the number of persons under-
going I-131 treatment (RIZIV/INAMI) in the hospital were
used.
Hormone treatment (such as with levothyroxine) is used
mainly to treat hypothyroidism in Belgium. It is used much
less frequently for multinodular goiter or thyroid nodules.
Therefore data relating to this were not used in the analysis. In
2008 there were 20,313 adults (18 years) in Belgium who
were reimbursed for the use of antithyroid medications
(58,196 packages of methimazole as thiamazol or Struma-
zol). In addition, 45,436 packages of propylthiouracil (PTU)
were used by adults in the same year and it was estimated that
the average number of packages per person per year was 18.
This medication is not reimbursed by the RIZIV/INAMI. The
prevalence of hyperthyroidism due to Graves’ disease in
Denmark was *40%, whereas the prevalence of hyperthy-
roidism due to multinodular goiter was 50% (34). Therefore, it
is estimated that 50% of the packages ofmethimazole and 50%
of the packages of propylthiouracil were used to treat hy-
perthyroidism secondary to multinodular goiter or autono-
mous thyroid nodules in Belgium. Based on the number of
packages of methimazole (either generic or brand name)
whose cost was reimbursed in Belgium in 2008, the costs of
these were estimated to be e320,228. Therefore, considering
that half of the use of this drug was for thyrotoxic nodular
thyroid disease, the reimbursement for the use of methima-
zole to treat thyrotoxic nodular thyroid disease was estimated
to be e160,114.
I-131 therapy is widely used for the treatment of hyper-
thyroidism due to autonomous thyroid nodules and multi-
nodular goiter in Belgium. It is used much less frequently for
treatment of thyroid cancer and Graves’ disease. The mean
number of treatmentswith I-131 over the years 2003–2007was
4300, with an average total cost per year of e979,537.
In addition to treatment costs, there are costs for the diag-
nosis and follow-up of multinodular goiter and thyroid
nodules. The only available data are those for diagnosis and
follow-up by specialists. General practitioners also follow
patients with nodular thyroid diseases, but blood tests and
other tests for diagnosis of thyroid diseases (ultrasound,
thyroid scan, and thyroid uptake) are exclusively performed
by specialists. Costs related to diagnosis and follow-up by
specialists were received from RIZIV/INAMI. The average
number of cases and the total related average costs of diag-
nosis and follow-up in a hospital setting for the period 2003–
2007 are presented in Table 3. The total average cost per year
related to diagnosis and follow-up by specialists of the above-
mentioned pathologies was estimated to be e23,267,693.
Results
The total annual TC caused byMID in the adult population
in Belgium, including surgery (e13,128,807), diagnosis and
follow-up (23,267,693), medicines and hormone treatment
(e160,114), and I-131 treatment (e979,537) amounted to
e37,536,151. The total PC in Belgium, including monitoring
Table 2. Costs in Euros for Surgery Due to Thyroid Nodular Diseases in Belgium 2005–2007
Year
Number of
hospital stays
Number of
hospital days A B Total costs
2005 4712 20,785 e6,321,419 e6,088,117 e12,409,536
2006 4770 20,255 e6,490,184 e6,531,599 e13,021,783
2007 4946 20,199 e6,762,609 e7,192,494 e13,955,103
Av/Y 4809 20,413 e6,524,737 e6,604,070 e13,128,807
Av/Y, average costs per year; A, costs related to stays in the hospital; B, costs related to blood tests, metabolic therapy, use of
pharmaceuticals, diagnosis tests, and clinical biology.
Source: Link between Data Federal Public Service of Health and RIZIV/INAMI.
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(e260,000) and social marketing (e10,000), were estimated to
be e270,000 over a 4–5-year period (Table 4).
To calculate the saved costs per year after a 4-year period
having the iodization program in place, it was assumed that
prevalence of multinodular goiter and thyroid nodules will
decrease by 38% in Belgium as was the case in Denmark with
a similar intervention in place (33). The net saved costs per
year, due to the optimization of iodine intake in Belgium, can
consequently be calculated as follows:
0.38(total TC in the adult population in Belgium) (total
PC including monitoring/5)¼ 0.38e37,536,151 e270,000/
5¼ e14,209,737 (Tables 4 and 5).
Discussion
Our analysis indicates that the saved costs after the im-
plementation of an iodization program in a country suffering
fromMID can be considerable. In this study in Belgium the net
benefit of such a program would be around e14 million.
Nevertheless, these findings have to be interpreted with
caution. One of the limitations of this study is that prevalence
data from another country were used to perform the calcu-
lations. In future, efforts should be undertaken to collect
prevalence data on thyroid nodular diseases in Belgium.
Further, it needs to be stressed that many costs were not
included, such as costs due to better cognition and higher
productivity, and costs due to work disability (absence from
work), as specified in the methods section, but it makes the
estimation reliable and conservative.
It should be noted also that only 1.8% of the adult persons
suffering from thyroid nodules or multinodular goiter are
treated with antithyroid medication or I-131 iodine therapy
and only 0.33% undergo surgery. This indicates that a high
number of adult persons are probably not aware that they
have nodular thyroid disease.
Conclusion
The yearly costs related to MID in the Belgian adult pop-
ulation are *e38 million. It is expected that the iodization
program will decrease the prevalence of thyroid nodular
disease with 38% after a 4–5-year period. Due to this, it will be
possible to save at least e14 million a year.
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